Back

EDP167, an ANGPTL3-target siRNA, showed favorable safety and lipid-lowering potential in Chinese healthy adult volunteers and subjects with mild dyslipidemia

30 August 2026 (10:15 - 11:00)
Organised by: Logo
Congress Presentation Part of: Lipid lowering and cardiovascular outcomes Lipid-Lowering Agents ESC2026 Premium Access ESC Congress 2026 European Society of Cardiology

About the speaker

Photo
Doctor Bo Jiang

The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou (China)

6 More presentations in this session

Presentation thumbnail
Gender-related differences in efficacy, safety and adherence of PCSK9 inhibitors in real-world clinical practice: insights from the AT-TARGET-IT Registry
Professor P. Perrone-Filardi (Naples, IT)
Abstract
Presentation thumbnail
Sustained combination lipid-lowering therapy determines durability of LDL-C <55 mg/dL after ACS: a structured implementation study (2022–2026)
Doctor K. Mahajan (Mandi, IN)
Abstract
Presentation thumbnail
Statin therapy and 1-year mortality in non-ischaemic acute myocardial injury: a dual-cohort study
Doctor T. Yang (Tianjin, CN)
Abstract
Presentation thumbnail
Pooled on treatment lipid lowering efficacy of the CETP inhibitor obicetrapib in phase III trials
Mr M. De Kleer (Amsterdam, NL)
Abstract
Presentation thumbnail
Effect of apolipoprotein B reduction on major adverse cardiovascular events in randomized controlled trials of triglyceride-lowering therapies: systematic review and exploratory meta-regression
Doctor M. Sobral Domingues (Lisbon, PT)
Abstract

Access the full session

Session thumbnail
Lipid lowering and cardiovascular outcomes

The Event

Event poster

ESC Congress 2026

30 August 2026 10:15 CET
You may be interested in
thumbnail
Congress Presentation
Safety and efficacy of zodasiran, a hepatic sirna targeting angptl3, in mixed hyperlipidemia patients: 2 year open label extension (OLE) results from ARCHES-2
31 August 2025
thumbnail
Congress Presentation
BW-00112 targeting ANGPTL3 results in prolonged reductions in plasma triglycerides, LDL-C, and remnant-C in Chinese healthy subjects
29 August 2025
thumbnail
Congress Presentation
Identification of six novel susceptibility loci for dyslipidemia by longitudinal exome-wide association studies in japanese
29 August 2020
thumbnail
Congress Presentation
Active-target liposomal drug shows significant atherosclerotic plaque regression effect: a proof-of-concept phase 1b/2a clinical trial
1 September 2025

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources